Coherus’ new focus on oncology leads to restructuring, 30% layoffs

Co­herus Bio­Sciences is lay­ing off about 30% of its staff by the end of the year, fol­low­ing its plan to fo­cus on on­col­o­gy and its sale of oph­thal­mol­o­gy biosim­i­lar Cimer­li to San­doz.

In its full-year earn­ings, Co­herus said Wednes­day that a “sharp­ened fo­cus in on­col­o­gy and a sub­se­quent re­struc­tur­ing” would lead to the lay­offs, with about 35 of those po­si­tions linked to the sale of Cimer­li. Co­herus es­ti­mat­ed it will save the com­pa­ny more than $25 mil­lion in an­nu­al­ized cost sav­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.